Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 7/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 4/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557051 | 0.90 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL6223554 | 0.84 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5557262 | 0.83 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5553028 | 0.82 | PDE4B (0.56) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5552794 | 0.81 | PDE4A (0.82) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL5559134 | 0.80 | CNR2 (0.59) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL24437232 | 0.80 | HTR3A (0.46) | PDE4APDE4BPDE4CPDE4DELANE | |
| SCHEMBL3534667 | 0.79 | HTR3A (0.47) | ELANEHTR3ACNR2CNR1 | |
| SCHEMBL5557942 | 0.79 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DKCNH2 | |
| SCHEMBL1606716 | 0.78 | NPC1 (0.49) | ELANECNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169787-B2 | 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | ELBION AG (DE) | 2007-01-30 | — | — | US | claimed |
| EP-1330455-B1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | ELBION AG (DE) | 2005-08-03 | — | — | EP | claimed |
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | BIOTIE THERAPIES GMBH (DE) | 2004-06-03 | — | — | US | claimed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | PDE4A, PDE4B, PDE4C | PDE4A 1/4885PDE4B 2/4885PDE4C 3/4885 |
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | PDE4A 2283/4885PDE4B 2265/4885PDE4C 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.